Generic Surge Erodes Eli Lilly’s Dominance in India’s GLP-1 Market

Eli Lilly's lead in India's GLP-1 market is narrowing as the entry of affordable generic alternatives disrupts the pricing landscape. Data from industry provider Pharmarack indicates Lilly's market share dropped to 56% in March, down from 61% the previous month, while rival Novo Nordisk held steady at 25%. The shift follows the expiration of the patent for semaglutide, the active ingredient in Novo Nordisk's flagship drugs. This has paved the way for 13 Indian generic manufacturers to launch 26 different brands in a matter of weeks, offering significantly cheaper alternatives for diabetes and obesity management in a country where nearly a quarter of the population is classified as overweight or obese. The cost disparity has become a primary driver of the market shift. Eli Lilly’s Mounjaro is priced at approximately 13,800 rupees ($148) per month, which is more than double the cost of Novo Nordisk’s semaglutide products and ten times the price of the cheapest generics, which start at 1,290 rupees. To defend its territory, Novo Nordisk implemented deep price cuts, reducing the cost of Ozempic by 38% and Wegovy by 48%. These moves have narrowed the gap between branded and generic versions, allowing the Danish firm to retain its market position. Analysts suggest that while tirzepatide remains more effective, it may increasingly be restricted to wealthier patients. With India's GLP-1 market projected to grow nearly five-fold to 50 billion rupees by 2030, the battle between premium efficacy and affordability will define the region's pharmaceutical landscape.